source
- FDA approves Regeneron's Livsayis, first RNAi therapy for generalized myasthenia gravisThe Food and Drug Administration approved Regeneron's Livsayis, an RNA interference drug for generalized myasthenia gravis, marking the company's first marketed RNAi therapy. The drug, originally…
- Study finds malaria antibody L9LS reduces vaccine response in infantsResearchers in Mali tested the monoclonal antibody L9LS in infants to see if it could protect against malaria and complement the R21 vaccine. The trial showed L9LS provided about 78% protection ov…